Dendreon Corporation's Provenge Vaccine, A Hedge Fund Manager And The SEC
Published: Dec 04, 2013
In a curious postscript to the long-running saga that has been the Provenge vaccine, the US Securities and Exchange Commission has levied a $25,000 fine on a former hedge fund analyst, who caused a stir by writing a medical study that questioned the benefit of the medicine and, subsequently, claimed she received threatening remarks on investor message boards.
Hey, check out all the research scientist jobs. Post your resume today!